Navigation Links
AlphaVax Continues to Expand the Use of Its Vaccine Platform
Date:6/6/2008

RESEARCH TRIANGLE PARK, N.C., June 6 /PRNewswire/ -- AlphaVax, Inc. recently received notification from the National Institute of Allergies and Infectious Diseases (NIAID), one of the granting institutes of the National Institutes of Health (NIH), that it has been awarded a second grant to continue development of a smallpox vaccine based on AlphaVax's proprietary vector platform. The grant will support additional studies in rodents and non- human primates to further characterize the high-level protection observed previously in these species.

Work completed during the first grant period demonstrated that AlphaVax's smallpox vaccine, which expresses four, highly conserved poxvirus proteins, could provide humoral responses comparable to those obtained with a licensed vaccine. Furthermore, the AlphaVax vaccine protected mice against vaccinia virus challenge and non-human primates against a lethal challenge with monkeypox virus. The details of this work will be presented by Dr. Kurt Kamrud, Director of Discovery Research at AlphaVax and the Principal Investigator on both grants, at the XVII International Poxvirus and Iridovirus Conference in Grainau, Germany on June 7-12th, 2008.

"The work completed under the NIAID grant to date is an excellent demonstration of the potential of our alphavirus vector platform to address many different diseases as well as bioterrorism threats. We have shown efficacy of this platform in numerous animal models and safety and immunogenicity in three clinical trials to date. We look forward to working with the U.S. Government to advance a new smallpox vaccine that has an excellent safety profile and is capable of being rapidly manufactured using AlphaVax's proprietary manufacturing process," said Dr. Jonathan F. Smith, Chief Scientific Officer at AlphaVax.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs. In addition to cytomegalovirus, important disease targets include influenza, cancer, HSV, RSV, and a number of biodefense vaccine products. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC.

About NIH Grant Support

The work described was supported by Grant Number UC1AI067183-01 from the National Institute of Allergy And Infectious Diseases. The content of this press release is solely the responsibility of AlphaVax and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institutes of Health.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
2. AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
3. Replidyne Discontinues Phase III Trial
4. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
5. Medarex Announces Ipilimumab Program Continues to Move Forward
6. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
7. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
8. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
9. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
10. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
11. Gilbert Hospital Continues Cutting Edge Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):